Skip to content
OpenCapital
Get started

Acadia Pharmaceuticals ACAD EV / sales

EV / sales at other companies

Biogen logo
BiogenBIIB
3×+0.8×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
4.3×-0.4×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
3.8×-0.6×
PTC Therapeutics logo
PTC TherapeuticsPTCT
6.3×+4.6×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
28.9×-18.5×
TG Therapeutics logo
TG TherapeuticsTGTX
8×-8.3×

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M—
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0×0.0×
Current ratio3.6×+0.7×

Where this comes from

Calculated from Acadia Pharmaceuticals’s reported figures.

enterprise value/total revenue=3.3×

Based on the most recent quarter.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's EV / sales?
Acadia Pharmaceuticals (ACAD) reported EV / sales of 3.3× in Q1 2026.
How has Acadia Pharmaceuticals's EV / sales changed year-over-year?
Acadia Pharmaceuticals's EV / sales increased by 24.3% year-over-year, from 2.6× to 3.3×.
What is the long-term trend for Acadia Pharmaceuticals's EV / sales?
Over 5 years (2020 to 2025), Acadia Pharmaceuticals's EV / sales has grown at a -26.3% compound annual growth rate (CAGR), from 18.8× to 4.1×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.